DDInter298 DDInter1335
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.
Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the plant, Cephalotaxus species. In October 2005, omacetaxine mepesuccinate received Orphan Drug designation from the EMEA for the treatment of chronic myeloid leukemia (CML). Then in March 2006, it received Orphan Drug status from the FDA for the treatment of CML. In November 2006, omacetaxine mepesuccinate, for the treatment of CML, was granted Fast Track designation by the FDA. Most recently, in October 2012, omacetaxine mepesuccinate was marketed under the brand name Synribo and FDA approved for patients who are intolerant and/or resistant to two or more tyrosine kinase inhibitors used to treat accelerated or chronic phase CML.
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is treated by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) downregulates {v} (Gene) ZNF23
ZNF23 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is associated with {v} (Gene) NFE2L2
NFE2L2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin {u} (Compound) treats {v} (Disease) ovarian cancer
ovarian cancer {u} (Disease) upregulates {v} (Gene) SQSTM1
SQSTM1 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin {u} (Compound) treats {v} (Disease) esophageal cancer
esophageal cancer {u} (Disease) is associated with {v} (Gene) FKBP1A
FKBP1A {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin {u} (Compound) treats {v} (Disease) breast cancer
breast cancer {u} (Disease) is associated with {v} (Gene) and {u} (Disease) upregulates {v} (Gene) HIST1H2BK
HIST1H2BK {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) is bound by {v} (Compound) Cisplatin
Cisplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Omacetaxine mepesuccinate
Carboplatin {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) is bound by {v} (Compound) Nabumetone
Nabumetone {u} may lead to a major life threatening interaction when taken with {v} Omacetaxine mepesuccinate
Carboplatin {u} (Compound) binds {v} (Gene) GSTM1
GSTM1 {u} (Gene) regulates {v} (Gene) TP53BP2
TP53BP2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin {u} (Compound) binds {v} (Gene) MPO
MPO {u} (Gene) regulates {v} (Gene) CDC25B
CDC25B {u} (Gene) is downregulated by {v} (Compound) Omacetaxine mepesuccinate
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is treated by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) downregulates ZNF23 (Gene) and ZNF23 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is associated with NFE2L2 (Gene) and NFE2L2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Carboplatin (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) upregulates SQSTM1 (Gene) and SQSTM1 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Carboplatin (Compound) treats esophageal cancer (Disease) and esophageal cancer (Disease) is associated with FKBP1A (Gene) and FKBP1A (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Carboplatin (Compound) treats breast cancer (Disease) and breast cancer (Disease) is associated with HIST1H2BK (Gene) and breast cancer (Disease) upregulates HIST1H2BK (Gene) and HIST1H2BK (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) is bound by Cisplatin (Compound) and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Carboplatin (Compound) binds MPO (Gene) and MPO (Gene) is bound by Nabumetone (Compound) and Nabumetone may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate
Carboplatin (Compound) binds GSTM1 (Gene) and GSTM1 (Gene) regulates TP53BP2 (Gene) and TP53BP2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Carboplatin (Compound) binds MPO (Gene) and MPO (Gene) regulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)